期刊
ANALYTICAL BIOCHEMISTRY
卷 634, 期 -, 页码 -出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ab.2021.114291
关键词
CGRP; Migraine; Monoclonal antibody; Bioassay; Reporter gene assay
资金
- National High Technology Research and Development Program of China [2018ZX09101001-003]
A reporter gene assay (RGA) was developed in this study for bioactivity determination of CGRP antibodies, demonstrating good specificity, accuracy, and precision in accordance with ICH-Q2 guidelines. This method can be utilized for quality control and clinical application of therapeutic antibodies targeting CGRP.
Calcitonin gene-related peptide (CGRP) is critical for the pathophysiology of migraine, and four therapeutic antibodies targeting CGRP and its corresponding receptors have been approved by the Food and Drug Administration (FDA), while many others are in the different stages of clinical trials. Bioactivity determination is essential for the quality control and clinical application of therapeutic monoclonal antibodies (mAbs). However, no bioassay has been reported to date. In this study, we developed a reporter gene assay (RGA) based on SK-N-MC cells stably expressing firefly luciferase driven by cAMP response element (CRE). The key assay parameters were optimized according to signal-to-noise (SNR), the response value, and the fitted dose-response curve. Validation of the RGA in accordance with ICH-Q2 guidelines showed that the method had good specificity, accuracy, linearity, and precision. The established RGA can be utilized as a reference method for release testing and stability studies of relevant antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据